iShares US Healthcare ETF

IYH

Börsenwert 4,17 Mrd. $

The iShares U.S. Healthcare ETF offers a lower expense ratio and a higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides concentrated exposure to over 200 biotech companies, while the iShares U.S. Healthcare ETF holds 100 diverse healthcare positions.

iShares Global Healthcare ETF provides broad exposure to international medical companies with a higher dividend yield than its domestic counterpart. iShares U.S. Healthcare ETF concentrates on American companies and has produced higher total returns over the past year and five-year periods.

The Invesco Nasdaq Biotechnology ETF carries a lower expense ratio and delivered higher total returns over the trailing 12 months than the iShares U.S. Healthcare ETF. The iShares U.S. Healthcare ETF provides broader industry diversification across the medical sector, while the Invesco Nasdaq Biotechnology ETF focuses strictly on biotechnology and pharmaceuticals.

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Nine of the 16 Big Pharma stocks covered in this article set new 52-week highs during August, reflecting strong momentum across the sector. Also, the rally has been driven by strong Q2 results, as well as Wall Street's growing shift toward healthcare amid continued geopolitical tensions in the Middle East.

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on June 12, 2000.

The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure across the healthcare sector, whereas the VanEck Pharmaceutical ETF (NYSEMKT:PPH) concentrates specifically on pharmaceutical stocks. PPH offers a slightly lower expense ratio and a higher dividend yield than IYH.

Simplify Health Care ETF has significantly outperformed iShares U.S. Healthcare ETF on a 1-year total return basis. iShares U.S. Healthcare ETF offers a lower expense ratio and a higher trailing-12-month dividend yield.